Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 11INDUSTRY 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Stomach Neoplasms 12Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Sarcoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1NSCLC 1Metastatic Castration Resistant Prostate Cancer 1Malignant Neoplasms of Digestive Organs 1Fallopian Tube Neoplasms 1Cytochrome P450 Interaction 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced Primary Liver Cancer 1Advanced Cancer 1

Interventions

Doxorubicin 33pembrolizumab 16Gemcitabine 15eribulin 10Irinotecan 10olaratumab 9Trabectedin 9pazopanib 8Docetaxel 8Injections 7Cyclophosphamide 7Nivolumab 6Fluorouracil 6anlotinib 5Temozolomide 5Ipilimumab 5Ifosfamide 5Bevacizumab 5tazemetostat 4ridaforolimus 4Drug Therapy 4Cetuximab 4Carboplatin 4toripalimab 3surufatinib 3spartalizumab 3ganitumab 3entrectinib 3conatumumab 3belinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma × apatinib × Clear all
NCT03711279 2024-02-29

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
99 enrolled 10 charts
Sarcoma

Sarcoma

NCT04074564 2023-10-23

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase EARLY_PHASE1 Unknown
60 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡